SMTI Shariah Compliance
Screening Methodology: AAOIFI
HALAL
Last Updated: March 31, 2026
Report Source: 2025 Annual Report
Sanara Medtech Inc. Stock Analysis SMTI
Sanara MedTech, Inc. engages in the development, marketing, and distribution of biotechnology products to physicians, hospitals, and clinics. The company is headquartered in Fort Worth, Texas and currently employs 108 full-time employees. Its Sanara Surgical segment primarily markets and sells soft tissue repair and bone fusion products for use in the operating room or other sterile environments. Its Tissue Health Plus segment is focused on value-based wound care services. The company markets and distributes CellerateRX Surgical Activated Collagen, FORTIFY TRG Tissue Repair Graft and FORTIFY FLOWABLE Extracellular Matrix as well as a portfolio of advanced biologic products focusing on ACTIGEN Verified Inductive Bone Matrix, ALLOCYTE Plus Advanced Viable Bone Matrix, BiFORM Bioactive Moldable Matrix, TEXAGEN Amniotic Membrane Allograft, and BIASURGE Advanced Surgical Solution to the surgical market. BIAKOS Antimicrobial Wound Gel and others are the products sold in the wound care market.
Read More Sanara Medtech Inc (SMTI) Chart
Key Statistics of Sanara Medtech Inc (SMTI)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$21.58Volume
36.88KP/E Ratio (TTM)
-52 Week Range
Market Cap
179.81MAvg. Volume
51.65KDividend Yield
-Financial Metrics & Statements of Sanara Medtech Inc (SMTI)
FAQ's for Sanara Medtech Inc (SMTI)
- According to Musaffa’s Shariah screening methodology, Sanara Medtech Inc (SMTI) is currently classified as HALAL as of March 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.